Levossimendano Kabi (Levosimendan)

Levosimendan is employed in the management of heart failure syndromes where enhanced contractility is required.

• Acute decompensated heart failure: increases cardiac output and relieves pulmonary congestion.
• Severe chronic heart failure (when standard therapy is insufficient): provides additional inotropic support.
• Heart failure with reduced ejection fraction: helps maintain systemic perfusion during acute decompensation.

• Levosimendan binds to cardiac troponin C, increasing its sensitivity to calcium and thereby enhancing myocardial contractility without raising intracellular calcium levels. Simultaneously, it opens ATP‑sensitive potassium channels in vascular smooth muscle, causing arterial and venous dilation, which reduces cardiac preload and afterload, improving overall cardiac efficiency.

Levosimendan may be associated with a range of adverse reactions.

Common Side Effects

• Hypotension: mild to moderate blood pressure drop.
• Headache: transient cranial discomfort.
• Nausea: occasional upset stomach.
• Dizziness: feeling light‑headed.
• Vomiting: occasional emesis.
• Tachycardia: increased heart rate.

Serious or Rare Side Effects

• Arrhythmias: potentially life‑threatening rhythm disturbances.
• Myocardial ischemia: reduced heart muscle blood flow.
• Severe hypotension: marked blood pressure fall requiring intervention.
• Allergic reactions: rash, pruritus, or anaphylaxis.
• Pulmonary edema: fluid accumulation in lungs.
• Liver enzyme elevation: abnormal hepatic function tests.

Levosimendan should be used with careful clinical monitoring.

• Hemodynamic monitoring: continuous blood pressure and ECG assessment.
• Concomitant vasodilators: avoid excessive hypotension when combined.
• Pre‑existing arrhythmias: assess risk before initiation.
• Severe renal or hepatic impairment: dose adjustment may be required.
• Pregnancy and lactation: safety not established; use only if benefits outweigh risks.
• Store at ambient temperature: keep in original container, protect from moisture and light.

Levosimendan may interact with several drug classes.

Major Interactions (Avoid)

• Strong vasodilators (e.g., nitroglycerin): risk of profound hypotension.
• Potassium channel blockers: additive vasodilatory effect.
• Anti‑arrhythmic agents (e.g., amiodarone): potential for arrhythmia exacerbation.

Moderate Interactions (Monitor Closely)

• Beta‑blockers: may blunt desired inotropic response.
• Diuretics: monitor electrolyte balance and blood pressure.
• ACE inhibitors/ARBs: watch for additive blood pressure effects.